Latest News-Zhongshan Kangfang Biological Medicine Co., LTD Mediaroom_Page

First Patient Enrolled in the US Phase 2 Combination Therapy of Akeso's Ligufalimab with Azacitidine for Myelodysplastic Syndrome

HONG KONG, Aug. 6, 2024 /PRNewswire/ -- Akeso has announced the completion of the first patient enr...

2024-08-06 12:44 2659

Akeso's sBLA for Ivonescimab in 1L Treatment of PD-L1 Positive NSCLC Accepted by NMPA

HONG KONG, July 29, 2024 /PRNewswire/ -- Akeso (9926.HK) is delighted to announce that the suppleme...

2024-07-29 17:26 2846

Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for 2L+ EGFRm NSCLC based on HARMONi-A Clinical Trial: Positive Trend Observed in Overall Survival towards Ivonescimab Plus Chemotherapy

Separate & Distinct from HARMONi-2 Announcement, HARMONi-A Showed Clinically Meaningful and Statist...

2024-06-01 19:10 4602

Ivonescimab Monotherapy Decisively Beats Pembrolizumab Monotherapy Head-to-Head, Achieves Statistically Significant Superiority in PFS in First-Line Treatment of Patients with PD-L1 Positive NSCLC

* Monotherapy Ivonescimab Achieved Clinically Meaningful PFS Benefit in HARMONi-2 Trial Conducted...

2024-05-31 02:21 3404

Oral report | The positive interim analysis results from the Phase III clinical study of Akeso's Cadonilimab (PD-1/CTLA-4 BsAb) plus chemotherapy as first-line treatment for advanced gastric cancer presented at 2024 AACR

SAN DIEGO, April 8, 2024 /PRNewswire/ -- Akeso, Inc. (9926.HK) today announced thatthe positive int...

2024-04-09 04:53 2954

Akeso Announced the First Patient Dosed in Phase III Trial of Cadonilimab(PD-1/CTLA-4) Combined with Chemotherapy versus Tislelizumab Combined with Chemotherapy in First-line Treatment of PD-L1 negative NSCLC

HONG KONG, March 6, 2024 /PRNewswire/ -- Akeso Inc. ("Akeso", 9926. HK) announced the enrollment of...

2024-03-06 18:07 2885

The promising results of a phase II clinical study for Akeso's Cadonilimab (PD-1/CTLA-4) combined standard treatment for first-line treatment of R/M cervical cancer has been published in Clinical Cancer Research

HONG KONG, Feb. 28, 2024 /PRNewswire/ -- Akeso (9926.HK) announced that the results of a phase II c...

2024-02-28 17:27 2679

Akeso Presented Promising Results of Cadonilimab and Lenvatinib in Combination with TACE in uHCC at 2024 ASCO GI

HONG KONG, Jan. 23, 2024 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso," "we," or the "Company") to...

2024-01-23 21:00 4047

Akeso to Present at the 42nd Annual J.P. Morgan Healthcare Conference and Share Its Corporate & Innovative Clinical Development Roadmap

HONG KONG, Jan. 8, 2024 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso," "we," or the "Company") tod...

2024-01-08 21:38 2514

Supplemental New Drug Application for Akeso's Cadonilimab (PD-1/CTLA-4) Accepted by NMPA for First-line Treatment of Gastric Cancer

HONG KONG, Jan. 5, 2024 /PRNewswire/ -- Akeso (9926.HK) announced the China National Medical Produc...

2024-01-05 21:00 6805

Akeso Published Results from CD47 Antibody Ligufalimab in Combination with Azacitidine for Newly Diagnosed Higher-Risk Myelodysplastic Syndrome and Treatment-naïve Acute Myeloid Leukemia at ASH 2023

HONG KONG, Dec. 15, 2023 /PRNewswire/ -- Akeso published two phase Ib clinical results of its innov...

2023-12-15 21:00 2790

Results of three investigator-initiated trials on cadonilimab (PD-1/CTLA-4) for G/GEJC, pMMR/MSS mCRC, and HCC neoadjuvant therapy published at ESMO Asia 2023

First-line therapy for gastric cancer and metastatic colorectal cancer, neoadjuvant therapy for hep...

2023-12-05 21:00 2528

Akeso Launches Construction of Shanghai Global R&D Center to Accelerate Its Innovation Globalization Strategy

HONG KONG, Nov. 28, 2023 /PRNewswire/ -- The groundbreaking ceremony for Akeso (9926.HK) Shanghai ...

2023-11-28 21:00 3077

Cadonilimab (PD-1/CTLA-4 Bispecific Antibody) Met Primary Endpoint of Progression-Free Survival in Phase III Trial for First-Line Treatment of Recurrent/Metastatic Cervical Cancer in All-Comer Patients

HONG KONG, Nov. 27, 2023 /PRNewswire/ -- Akeso (9926. HK) has announced that the AK104-303 Phase II...

2023-11-27 21:30 2617

Akeso's Cadonilimab (PD-1/CTLA-4) Phase III Trial Meets Primary Endpoint at Interim Analysis Demonstrating Strong Overall Survival Benefit as First-line Treatment in All-comer Patients with Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC)

HONG KONG, Nov. 7, 2023 /PRNewswire/ -- Akeso (9926.HK) announced positive results from an interim...

2023-11-07 20:00 2600

Ivonescimab's Novel Mechanism of Action Highlighting Cooperative Binding to be Featured in Poster Presentation at SITC 2023

Potential First-in-Class Tetravalent Bispecific Antibody Demonstrates Enhanced Binding inthe Simult...

2023-11-02 20:00 1440

Journal of Thoracic Oncology Published Promising Results of Ivonescimab (PD-1/VEGF Bispecific) as First- or Second-line Therapy for Advanced or Metastatic Immunotherapy Naïve Non-Small-Cell Lung Cancer

HONG KONG, Oct. 30, 2023 /PRNewswire/ -- Akeso (9926.HK) announced that the results of a phase Ib c...

2023-10-30 20:00 3364

Phase Ib/II Results of Akeso's PD-1/CTLA-4 Bispecific Antibody for First-Line Treatment of Advanced Hepatocellular Carcinoma Published at 2023 ESMO

HONG KONG, Oct. 24, 2023 /PRNewswire/ -- Akeso announced poster presentation at the 2023 European S...

2023-10-24 20:00 2352

Phase 1a/1b Study Results of Akeso's PD-1/CTLA-4 Bispecific Antibody Published in Cell Reports Medicine, Highlighting Promising Efficacy in Solid Tumors Refractory/Relapsed to Standard Therapy

HONG KONG, Oct. 19, 2023 /PRNewswire/ -- Akeso (9926. HK) announced the publication of the phase 1a...

2023-10-19 20:00 2519

Akeso Announced The Lancet Oncology Publishes Promising Clinical Results from Cadonilimab in Patients with Advanced Solid Tumours (COMPASSION-03/AK104-201)

HONG KONG, Oct. 12, 2023 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso") announced that the results...

2023-10-12 20:00 2292